The standard DTP or DPT (diphtheria, pertussis (whooping cough) and tetanus) vaccine is acknowledged to be the deadliest of all vaccines, causing more disability, illness and the highest risks, even exceeding MMR (measles, mumps and rubella).
The U.S. Department of Health and Human Services set up the National Vaccine Injury Compensation Program (NVICP) in 1988 to compensate individuals and families of individuals injured by covered childhood vaccines. The VICP itself was adopted in response to a the pertussis portion of the DTP vaccine.
Since 1988, the program has been funded by an excise tax on every purchased dose of a covered vaccine. To win an award, a claimant must show a causal connection; if medical records show a child has one of several listed adverse effects soon after vaccination. The burden of proof is the civil-law preponderance-of-the-evidence standard, in other words a showing that causation was more likely than not.
As of May 2013, the VICP has paid out $2.7 billion for cases involving injury amongst all vaccines.It obliges drug companies that produce vaccines to contribute to the program by paying an excise tax on each dose of vaccine, based on potential risk.Although the taxes raised by the vaccine tax go into a “trust fund
,” this trust fund, like most government trust funds, is on paper only. According to the most recent report on the fund, November 2012
, the balance in the fund is nearly $3.5 billion.
Epidemiologists Admit Pertussis (Whooping Cough) Is Spreading And Vaccines Are The CauseWhooping cough, or pertussis, is spreading across the entire US at rates at least twice as high as those recorded in 2011 and epidemiologists and health officials are even admitting that the vaccines may be the cause.
The cause could very well be due to multiple loads of toxins delivered through the DTP vaccine which include, (but not limited to): formaldehyde, aluminum hydroxide, aluminum phosphate, thimerosal, and polysorbate 80. That means that every DTP vaccine contains carcinogenic, neurotoxic, immunotoxic and sterility agents just like many of this year’s flu vaccines. These chemicals then bioaccumulate in the child with each successive vaccine, further introducing an additional load of toxins with each injection.
Dangerous new strains of whooping cough bacteria are now evading Australia’s vaccine against the disease and entrenching a four-year epidemic that could soon spread overseas, Sydney scientists have found in research that raises questions about the national vaccine program.
The dangerous new strains of whooping cough bacteria were reported in March 2012. The vaccine, researchers said, was responsible. The reason for this is because, while whooping cough is primarily attributed toBordetella pertussis infection, it is also caused by another closely related pathogen called B. parapertussis, which the vaccine does NOT protect against. Two years earlier, scientists at Penn State had already reported that the pertussis vaccine significantly enhanced the colonization of B. parapertussis, thereby promoting vaccine-resistant whooping cough outbreaks.
According to the authors:
“… [V]accination led to a 40-fold enhancement of B. parapertussis colonization in the lungs of mice. Though the mechanism behind this increased colonization was not specifically elucidated, it is speculated to involve specific immune responses skewed or dampened by the acellular vaccine, including cytokine and antibody production during infection. Despite this vaccine being hugely effective against B. pertussis, which was once the primary childhood killer, these data suggest that the vaccine may be contributing to the observed rise in whooping cough incidence over the last decade by promoting B. parapertussis infection.”
Pertussis whooping cough is a cyclical disease with natural increases that tend to occur every 4-5 years, no matter how high the vaccination rate is in a population using DTP or Tdap vaccines on a widespread basis. Whole cell DTP vaccines used in the U.S. from the 1950’s until the late 1990’s were estimated to be 63 to 94 percent effective and studies showed that vaccine-acquired immunity fell to about 40 percent after seven years.
In the study cited above, the researchers noted the vaccine’s effectiveness was only 41 percent among 2- to 7-year-olds and a dismal 24 percent among those aged 8-12
The fact that many vaccines are ineffective is becoming increasingly apparent. Merck has recently been slapped with two separate class action lawsuits contending they lied about the effectiveness of the mumps vaccine
in their combination MMR shot, and fabricated efficacy studies to maintain the illusion for the past two decades that the vaccine is highly protective.
History of Adverse Events Associated With The DTP Vaccine
The whole-cell pertussis component is associated with a range of adverse events, including serious neurological consequences. Concerns about the safety of whole-cell pertussis vaccine date back to the 30s and 40s. By the 1950s, concern about potential adverse events led some researchers to begin searching for a more refined, acellular version of pertussis vaccine with less reactogenicity.Fertility has been declining rapidly since the 1950s in all countries of the world and the start of the change coincided with the introduction of the first mass vaccination programs. For instance, in the UK in 1947, a mass DPT vaccine campaign was initiated and in 1958, the first polio and diphtheria vaccines were brought in on a mass scale for all people under 15 years old.
In the early to mid-1970s, the safety of whole-cell pertussis came under increasing scrutiny both in the U.S. and abroad. Newly heightened concerns were in part related to reports published
in Great Britain and Germany linking whole-cell pertussis vaccine to long term neurologic effects.
In 1975, in response to the deaths of two infants within 24 hours after DTP vaccination, Japanese health authorities temporarily suspended the routine use of pertussis vaccine in infants, and soon after recommended that vaccination against pertussis start instead at age two years.
In Britain, while health authorities continued to recommend routine DTP immunization for infants, the public became increasingly wary of potential adverse effects, and many parents chose not to immunize their children.
From 1978 through 1981, a total of nine product liability lawsuits were filed against DTP manufacturers in the U.S.. For the single year 1982, however, 17 DTP lawsuits were filed; and by 1986, the number of pertussis productliability suits filed during the year reached an all-time high of 225. During a six-month period in 1984, in response to the growing liability crisis, two of the three manufacturers distributing DTP in the U.S. market B Wyeth and Connaught B dropped out.
In 1997, the DTP vaccine was taxed at the highest rate per dose – $4.56 – compared with $0.29 for polio and $0.06 for DT (without pertussis). Only the MMR vaccine, at $4.44 per dose, approaches the DTP in ‘taxation’. This is tacit acknowledgement by the government that the pertussis vaccine carries the highest risk of them all.
No Placebo-Controlled Trials of Whole-Cell Vaccine Since 1950 – All Post-Vaccination Research in The Last 60 Years Shows Health Damage
No randomised placebo-controlled trials of whole-cell vaccine have been performed since the 1950s, when diagnostic methods were different. Indeed, in the early 1990s, the Institute of Medicine (IOM), which spent 20 months studying all the available data on vaccinations, confirmed that no controlled clinical trials have ever been conducted to rule out whether the vaccine can cause chronic neurological damage, blood disorders, juvenile diabetes, Guillain-Barre paralysis and learning disabilities. With the most controversial vaccine in history, most questions about safety have never been asked.The only large-scale study ever conducted in the US, at University of California at Los Angeles in 1979, found that one in 875 doses of DTP is followed by convulsions, or an episode of shock or collapse, leading to death in the case of two babies (Pediatrics, 1981; 68: 650-60). As for brain damage, a Swedish study showed a rate of brain damage or death of one in 17,000 children (BMJ, 1967; 4: 320-3).
The IOM report concluded that: the triple shot definitely causes anaphylactic shock and extended periods of inconsolable crying or screaming evidence is consistent with a causal relationship between acute encephalitis (inflammation of the brain) and shock and unusual shock-like (hypotonia/hyporesponsive) reactions, causing total collapse (Stratton K, Adverse Events Associated with Childhood Vaccines; Evidence Bearing on Causality, Washington, DC: National Academy Press, 1993).
In 1993, The National Childhood Encephalopathy study: a 10-year follow-up reported on the medical, social, behavioural and educational outcomes after serious, acute, neurological illness in early childhood. The analysis found a four-fold increase in the estimated risk of encephalitis from the pertussis vaccine. The analysis showed the risk of encephalitis with the vaccine have been grossly underestimated.
Diphtheria and tetanus toxoids and whole-cell pertussis vaccine (DTP) and pediatric diphtheria and tetanus toxoids (DT) are not recommended for individuals 7 years of age or older due to increased adverse reactions. Yet in 1994, a study in the Family Practice Research Journal found that children 7 years of age or older are inadvertently receiving DTP or DT and were unnecessarily experiencing adverse reactions.
In another study in the The Journal of the American Medical Association
, children vaccinated with pertussis vaccine were six times more likely to develop asthma. In 2004, a study in the British Medical Journal
found that the prevalence of asthma and wheezing in non-vaccinated individuals was approximately 50% less at age 69-81 months than children who had 3 or more doses of with the Diptheria and tetanus vaccine.Researchers reported in the OSMA Journal
that the pertussis vaccine may cause lasting and permanent brain damage. Physicians are required to warn all responsible parties of vaccine recipients that pertussis vaccine may cause “lasting brain damage”, but rarely if ever to Physicians inform parents of this fact.
In the Journal of Pediatrics researchers found an association observed between the DTP vaccination of preterm infants and a transient increase or recurrence of apnea where they would stop breathing.
New England Medical Journal reported in 2001 that the DTP vaccine increases the risk of febrile seizures fivefold on the day of vaccination and that there are significantly elevated risks.
According to the Anti-Aging Manual: The Encyclopedia of Natural Health, DTP vaccines may cause Sudden Infant Death Syndrome (SIDS) – 85% in 1 -6 months, same as the 2-4-6-month DTP vaccinations risk; the death rate increases eight times within 3 days of injection; in one study 70% of SIDS deaths occurred within 3 weeks of DTP vaccinations causes reported adverse reactions in 100 per 1000 vaccinations (10%).
In a hard hitting editorial in the Indian Journal of Medical Ethics (IJME),Dr. Jacob Puliyel, head of pediatrics at St Stephens Hospital in New Delhi, reports on detailed investigation into the deaths of children in Bhutan, Sri Lanka, India and Vietnam following use of Pentavalent vaccine. This vaccine combines the Diphtheria, Pertussis, Tetanus or DTP vaccine. (See WHO Caught Falsely Stating Pentavalent Vaccine Was Safe After It Was Discontinued In Some Countries Due To Deaths In Children)
Several other research citations linking the DTP vaccines to diseasehave they cause complications in neurological systems, the central nervous system, sudden death, cervical lymphadenitis and convulsions.
Former FDA Commissioner David Kessler wrote in the Journal of the American Medical Association
that “only about 1% of serious adverse events are reported to the FDA.”
This study confirms the systematic under-reporting bias against vaccine adverse reactions. So we could reasonably multiply the incidence in VAERS reports by 100 to get a better handle on the magnitude of the problem. Apparently, no number of VAERS vaccine adverse reaction reports is sufficient to cause the FDA or CDC to raise a red flag or withdraw a vaccine from the market.Sources: